Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer
Authors:
Open Access
- 2 June 2020
- journal article
- research article
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 40 (6) , 3435-3444
Abstract
Background/Aim: Although it has been suggested that circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) might be used in a complementary manner in lung cancer diagnosis, limited confirmatory data are available. In this prospective study, we evaluated the diagnostic performance of each assay separately and in combination. Patients and Methods: From March 2018 to January 2019, patients with suspected primary lung cancer, who underwent routine lung cancer work-up and peripheral blood sampling, were prospectively enrolled in the study. Epithelial cell adhesion molecule and cytokeratin served as markers of CTCs. In terms of ctDNA analysis, single-nucleotide variants were evaluated via next-generation sequencing. Results: We analyzed 111 patients, including 99 with primary lung cancer and 12 with benign pulmonary disease. The median number of CTCs in 10 ml of blood was 3. The most frequently detected single nucleotide variants of ctDNA were TP53, CDKN2A, and EGFR. The diagnostic sensitivity of conventional tumor marker (combination of carcinoembryonic antigen/CYFRA 21-1/neuron-specific enolase) was 66.7%, while those of the ctDNA and CTC assays were 72.7% and 65.7%, respectively. The sensitivity of the CTC/ctDNA combination (95.0%) was significantly greater than those of the CTC (p<0.001), ctDNA (p<0.001), or conventional tumor marker (p<0.001) alone. Subgroup analysis revealed that the sensitivity of the combination assay was greater than those of the CTC or ctDNA assays alone, regardless of tumor stage or histopathology type. Conclusion: The CTC/ctDNA combination assay enhanced the sensitivity of primary lung cancer diagnosis. The combination assay strategy may be clinically useful and could enhance the early detection of lung cancer (ClinicalTrials.gov number: NCT03479099).Keywords
This publication has 37 references indexed in Scilit:
- How liquid biopsies can change clinical practice in oncologyAnnals of Oncology, 2019
- Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencingJournal of Cancer Research and Clinical Oncology, 2018
- An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancerExpert Review of Molecular Diagnostics, 2017
- The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor CharacteristicsJournal of Thoracic Oncology, 2016
- Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapiesPharmacology & Therapeutics, 2016
- Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?Annals of Oncology, 2014
- Circulating Tumor Microemboli Diagnostics for Patients with Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2014
- Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biologyPhysical Biology, 2012
- Cell-free nucleic acids as biomarkers in cancer patientsNature Reviews Cancer, 2011
- Screening for Epidermal Growth Factor Receptor Mutations in Lung CancerNew England Journal of Medicine, 2009